MDxHealth SA

Equities

MDXH

BE0974461940

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.47 ^USD	0.00%		+10.76%	-37.31%

Mar. 12	Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering	CI
Mar. 07	Piper Sandler Adjusts Price Target on MDxHealth to $7 From $6, Maintains Overweight Rating	MT

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

February 16, 2024 at 08:45 am EST

MDxHealth SA announced that Jan Pensaert has stepped down from the Board of Directors. His resignation was effective as of February 15, 2024. Mr. Pensaert?s resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

Latest news about MDxHealth SA

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering	Mar. 12	CI
Piper Sandler Adjusts Price Target on MDxHealth to $7 From $6, Maintains Overweight Rating	Mar. 07	MT
MDxHealth SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 06	CI
Transcript : MDxHealth SA, Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Earnings Flash (MDXH) MDXHEALTH Posts Q4 Revenue $19.4M	Mar. 06	MT
MDxHealth SA Maintains Earnings Guidance for the Year 2024	Mar. 06	CI
MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors	Feb. 16	CI
MDxHealth Preliminary Q4 Revenue Tops Consensus; 2024 Outlook Exceeds Estimates; Shares Jump After Hours	Jan. 08	MT
MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024	Jan. 08	CI

Chart MDxHealth SA

Duration

Period

More charts

Company Profile

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Companyâs tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.47 USD

Average target price

6.333 USD

Spread / Average Target

+156.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MDXHEALTH SA	-37.31%	67.4M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research